Fidelity SPDR Advertisement
Home > Boards > US Listed > Biotechs > Peregrine Pharmaceuticals (PPHM)

I don't know about the rest of you,

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
pphmtoolong Member Profile
 
Followed By 20
Posts 2,567
Boards Moderated 0
Alias Born 07/17/06
160x600 placeholder
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock "Marketwired" - 6/10/2014 4:00:00 PM
Peregrine Pharmaceuticals Announces Initiation of an Investigator-Sponsored Trial Combining Its Immunotherapy Bavituximab & I... "Marketwired" - 4/23/2014 7:30:00 AM
Healthcare Companies Report Results, Patents, and Stock Movements - Analyst Notes on Puma Biotechnology, Alnylam, INSYS Thera... "PR Newswire (US)" - 4/10/2014 12:28:00 PM
Data Presented at AACR Support Potential of Peregrine's PS-Targeting Immunotherapy Bavituximab to Enhance Anti-Tumor & Immune... "Marketwired" - 4/9/2014 11:00:00 AM
Morning Review on Top Gainers -- Research on Peregrine Pharma, Agios Pharma, Idenix Pharma, and Lexicon Pharma "PR Newswire (US)" - 4/8/2014 1:15:00 PM
Data Presented at AACR Support Potential of Combining Peregrine's PS-Targeting Immunotherapy Agent Bavituximab With Irradiati... "Marketwired" - 4/7/2014 8:00:00 AM
Peregrine Pharmaceuticals Announces Three Abstracts Accepted for Presentation at AACR 2014 Annual Meeting "Marketwired" - 4/1/2014 4:00:00 PM
Presentation at Annual Society of Surgical Oncology Meeting Updates Progress in Investigator-Sponsored Phase i/ii Trial of Pe... "Marketwired" - 3/14/2014 8:00:00 AM
Preclinical Data Presentations at Keystone Symposia Highlight Broad Immunotherapy Potential of Peregrine Pharmaceuticals' PS-... "Marketwired" - 3/13/2014 8:00:00 AM
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock "Marketwired" - 3/11/2014 4:10:00 PM
Data Presentations at Keystone Symposium Support Potential of Peregrine Pharmaceuticals' PS-Targeting Antibodies to Overcome ... "Marketwired" - 3/11/2014 8:00:00 AM
Peregrine Pharmaceuticals Reports Third Quarter Fiscal Year 2014 Financial Results and Recent Developments "Marketwired" - 3/7/2014 8:00:00 AM
Pre-Market Review of Top Gainers: Canadian Solar, Qihoo 360 Technology, Peregrine Pharma, Renren, and UTi Worldwide "PR Newswire (US)" - 3/5/2014 10:40:00 AM
Peregrine Pharmaceuticals PS-Targeting Immunotherapy Platform to Be Highlighted in Three Data Presentations at Keystone Sympo... "Marketwired" - 3/4/2014 4:00:00 PM
Peregrine Pharmaceuticals to Report Third Quarter Fiscal Year 2014 Financial Results Before Market Open on March 7, 2014 "Marketwired" - 2/27/2014 4:00:00 PM
Peregrine Pharmaceuticals Announces Partial Exercise of Overallotment Option in Connection With Preferred Stock Offering "Marketwired" - 2/27/2014 12:18:24 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 2/19/2014 4:11:21 PM
Peregrine Pharmaceuticals Announces Upcoming Events "Marketwired" - 2/19/2014 4:00:00 PM
Peregrine Pharmaceuticals Announces Closing of Preferred Stock Offering "Marketwired" - 2/19/2014 10:15:17 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 2/12/2014 5:23:36 PM
Securities Registration (section 12(b)) (8-a12b) "Edgar (US Regulatory)" - 2/12/2014 5:20:59 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) "Edgar (US Regulatory)" - 2/12/2014 5:01:05 PM
Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp) "Edgar (US Regulatory)" - 2/11/2014 8:10:52 AM
Peregrine Pharmaceuticals Prices Offering of Its Series E Preferred Stock "Marketwired" - 2/11/2014 8:00:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 2/6/2014 5:28:09 PM
pphmtoolong   Tuesday, 04/24/12 10:44:52 AM
Re: None
Post # of 187180 
I don't know about the rest of you, but I bought this stock based on Thorpe's approved patents and the early Bavi clinical studies.

It seems that Peregrine management and BOD have done everything reasonable to forward the Bavi agenda given the limited financial resources available. Running the trials overseas in Georgia and India could not have been easy, but they did it and got promising results. As in many other cases Bavi may not pan out in later stage trials. I don't blame management for trying with Bavi, and I don't blame management for the perversity of Mother Nature. I could blame them for excessive optimism, but the science seemed sound to them just as it seemed sound to us.

I don't like that managment has diluted the heck out of our stock, but I really don't buy any of the alternative financing plans I've seen presented here. I am a retired CPA; so I have some confidence assessment on this point.

If Bavi finally hits it out of the park with second line NSCLC, there is still a chance for us to make money. Otherwise, this has been a very expensive lesson in wishful thinking on biotechs. I blame only myself if Peregrine flops. I never should have thrown so much money into such a crap shoot.

Paul

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist